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Abstract 
The combination of increased incidence of drug-resistant strains of bacteria and a lack of novel drugs in 
development creates an urgency for the search for new antimicrobials. Initial screening of compounds from an 
in-house library identified two 6-bromoindolglyoxylamide polyamine derivatives that exhibited intrinsic 
antimicrobial activity towards Gram-positive bacteria, Staphylococcus aureus and S. intermedius with one of the 
compounds also displaying in vitro antibiotic enhancing properties against the resistant Gram-negative 
bacterium Pseudomonas aeruginosa. A series of 6-bromo derivatives were prepared and biologically evaluated, 
identifying analogues with enhanced antibacterial activity towards Escherichia coli and with moderate to 
excellent antifungal properties. The mechanism of action of one of the compounds was attributed to rapid 
membrane permeabilisation and depolarisation in both Gram-positive and Gram-negative bacteria.  
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1. Introduction 
Antibiotics have been the cornerstone of modern medicine saving lives by virtue of being able to cure infectious 
diseases and to prevent infections in those that are immune compromised.
1–4
 Their intense use has led to a surging 
increase in the incidence of antibiotic-resistant bacteria resulting in a desperate need for antibiotics with new 
mechanisms of action. A strategy for overcoming bacterial resistance is to identify compounds that can circumvent 
the drug-resistant phenotype, enhancing or restoring the activity of antibiotics that are currently ineffective.
1–3
 
Polyamine-containing derivatives have been previously reported to enhance the activity of antibiotics, with 
simple unsubstituted polyamines, such as spermine and spermidine, having been found to act synergistically 
with a range of antibiotics to enhance the kill of a number of different Gram-positive and Gram-negative 
bacteria, but at an extraordinarily high dose of 1 mM.
5,6
 A recent study on polyamine-containing natural 
products identified squalamine (1) and ianthelliformisamine C (2) (Fig. 1), as being intrinsically antimicrobial 
and also being able to enhance the activity of antibiotics.
7–9
 Ianthelliformisamine C (2) was shown to exhibit 
antimicrobial activity against Staphylococcus aureus and Klebsiella pneumoniae (MIC 12.5 and 12.5 µM, 
respectively) and to enhance the activity of doxycycline against both microbes (MIC 12.5 and 12.5, 
respectively) as well as Pseudomonas aeruginosa (MIC 3.12 µM). Mechanism of action studies suggest 
squalamine (1) functions by disruption of the outer-membrane of Gram-negative bacteria while 
ianthelliformisamine C (2), in contrast, inhibits efflux pumps.
7,10
 Being suitably intrigued by these findings and 
given our ongoing interest in biologically active polyamine derivatives,
11–14
 we screened an in-house library of 
polyamine alkaloids related to the natural product ianthelliformisamine C (2)) for antimicrobial and antifungal 
properties and for the ability to restore the antibiotic activity of doxycycline towards P. aeruginosa. Herein we 
present this preliminary data, a structure-activity relationship study that explores the influence of the polyamine core 
on observed intrinsic antimicrobial properties and the ability to potentiate the action of doxycycline, and mechanism 
of action studies that evaluated compound influence on membrane permeability and polarization. 
 
2. Results and Discussion 
Our screening identified two 6-bromoindolglyoxylamide compounds, spermine 3
13
 and spermidine 4
13
 (Fig. 1) that 
exhibited good antimicrobial activity against two Gram-positive strains bacteria Staphylococcus intermedius 
(MIC 3.125 and 3.125 µM, respectively) and S. aureus (MIC 6.25 and 3.125 µM, respectively) and moderate to 
strong antifungal activity towards Candida albicans (MIC 17.2 µM for 3) and Cryptococcus neoformans (MIC 
1.1 and 50 M, respectively) (Table 1). These two hits were then evaluated for the ability to enhance the 
antibiotic activity of doxycycline towards Pseudomonas aeruginosa ATCC 27853. While doxycycline alone is 
ineffectual against this bacterial strain (MIC  64 g/mL), a combination of doxycycline at 2 g/mL with 3 at 
6.25 µM was able to restore the action of the antibiotic (Table 2). Somewhat surprisingly, the closely related 
spermidine hit compound 4 was found to be completely ineffective at restoring the action of doxycycline. In an 
effort to further expand on these initial findings, we prepared a series of analogues 7–15 (Fig. 2) that explored 
the influence of the polyamine core on the observed biological activities.  
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Fig. 1. Structures of polyamines 1–4. 
 
2.1 Chemistry 
Synthesis of the target 6-bromoindolglyoxylamide derivatives 5, 6, 8 and 9 (Fig. 2) was achieved by a two-step 
sequence starting with reaction of 2-(6-bromo-1H-indol-3-yl)-2-oxoacetyl chloride (16)
15
 with di-tert-butyl 
hexane-1,6-diylbis((3-aminopropyl)carbamate),
14
 di-tert-butyl heptane-1,7-diylbis((3-
aminopropyl)carbamate),
14
 di-tert-butyl decane-1,10-diylbis((3-aminopropyl)carbamate)
14
 or di-tert-butyl 
dodecane-1,12-diylbis((3-aminopropyl)carbamate)
14
 to afford a series of Boc protected intermediates (Scheme 
1). These crude reaction intermediates were then directly subjected to Boc group deprotection, with TFA in 
CH2Cl2, to give tetraamine diamides 5, 6, 8 and 9 as their corresponding di-TFA salts (Scheme 1). The synthesis 
of 7 has been reported previously.
13
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Fig. 2. Structures of the indolglyoxylamide derivatives 5–15. 
 
 
Scheme 1 General method for the preparation of analogues 5, 6, 8 and 9. 
Reagents and conditions: a) Boc-protected polyamine (0.5 eq.), DIPEA (3 eq.), DMF, r.t., 48 h; b) TFA (0.2 mL), CH2Cl2 or 
MeOH (2 mL), r.t., 3 h. 
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Analogues 10–15 were prepared by PyBOP-mediated coupling of 6-bromoindole-3-glyoxylic acid (17)11,13 with 
spermidine, 1,4-diaminobutane, 1,12-diaminododecane, 4,7,10-trioxa-1,13-tridecanediamine, N,N-
dimethylethylenediamine or 2-morpholinoethylamine (Scheme 2). 
 
Scheme 2 General method for the preparation of analogues 10–15. 
Reagents and conditions: a) RNH2 (1 eq.), PyBOP (1 eq.), Et3N (6 eq.), DMF, r.t., 24 h, 20–82%. 
 
3. Results and Discussion 
The library of analogues were evaluated for activity against a variety of Gram-negative (Pseudomonas 
aeruginosa, Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii) and Gram-positive bacteria 
(Staphylococcus aureus and Staphylococcus intermedius) as well as two yeast strains (Candida albicans and 
Cryptococcus neoformans) (Table 1). As a general trend, those analogues with a polyamine core (3, 4, 5-9) 
exhibited more pronounced activity than the non-polyamine (13) or shorter chained (10,11,12,14,15) 
derivatives. Within the polyamine examples, the presence of only one mid-chain nitrogen (4) reduced potency 
towards yeast, while the length of the polyamine mid-section gave maximal potency at PA3-10-3, with 8 
exhibiting relatively broad-spectrum activity.  
Table 1. Antibacterial and antifungal activities of indolglyoxylamide derivatives 3–15. 
 
MIC (M) 
P. aa E. cb S. ac S. id K. pe A. bf C. ag C. nh 
3 100 100 6.25 3.125 >34
 i >34 i 17.2 1.1 
4 >200 50 3.125 3.125 >50
 i >50 i >50 i 50 
5 52.2 >200 6.5 n.t.
j >32 >32 8.35 33.4 
6 51.4 51.4 6.4 n.t. >32 >32 16.5 >32 
7 50 6.25 50 12.5 >32 >32 8.11 32.4 
8 24.6 24.6 12.3 n.t. 31.5 31.5 1.97 <0.25 
9 >200 >200 >200 n.t. >32 >32 7.67 7.67 
10 >200 >200 12.5 50 >52
 i >52 i >52 i >52 i 
11 >200 >200 >200 >200 >54
 i >54 i >54 i >54 i 
12 >200 >200 >200 100 >46
 i >46 i >46 i >46 i 
13 >200 >200 >200 12.5 >44
 i >44 i >44 i >44 i 
14 >200 >200 >200 12.5 >95
 i >95 i >95 i >95 i 
15 >200 >200 >200 12.5 >84
 i >84 i >84 i >84 i 
 6 
 
a Pseudomonas aeruginosa ATCC 27853 with streptomycin (MIC 21.5 μM) and colistine (MIC 1 μM) used as positive 
controls and values presented as the mean (n = 3). 
b Escherichia coli ATCC25922 with streptomycin (MIC 21.5 μM) and colistine (MIC 2 μM) used as positive controls and 
values presented as the mean (n = 3). 
c Staphylococcus aureus ATCC 25923 with streptomycin (MIC 21.5 μM) and chloramphenicol (MIC 1.5–3 μM) used as 
positive controls and values presented as the mean (n = 3). 
d Staphylococcus intermedius 1051997 with streptomycin (MIC 10.7 μM) and chloramphenicol (MIC 3–6 μM) used as 
positive controls and values presented as the mean (n = 3). 
e Klebsiella pneumoniae ATCC 700603 with values presented as the mean (n = 2). 
f Acinetobacter baumanii ATCC 19606 with values presented as the mean (n = 2). 
g Candida albicans ATCC 90028 with values presented as the mean (n = 2). 
h Cryptococcus neoformans ATCC 208821 with values presented as the mean (n = 2). 
i Not active at a single dose test of 32 µg/mL. 
j Not tested. 
 
We next evaluated the library of compounds for the ability to enhance the activity of doxycycline towards P. 
aeruginosa (Table 2). In the presence of doxycycline (2 g/mL), polyamines 5 and 8 were found to have strong 
enhancing effects (6.52 M and 6.16 M, respectively), with 6 and 7 being slightly less efficient. The absence 
of potentiating activity for not only non-polyamine analogues 10–15 but also polyamine analogue 9 and 
spermidine 4 implies narrow structural specificity for the observed activity.  
Table 2. Doxycycline potentiation activity of indolglyoxylamide derivatives 3–15. 
Compound 
Conc (µM) for 
potentiationa 
3 6.25 
4 >200 
5 6.52 
6 12.9 
7 25 
8 6.16 
9 >200 
10 >200 
11 >200 
12 >200 
13 >200 
14 >200 
15 >200 
a Concentration (µM) required to restore doxycycline activity at 2 g/mL (4.5 µM) against P. aeruginosa ATCC 27853. 
 
Analogue 3 was also found to strongly potentiate the activity of doxycycline towards Gram-negative bacteria 
Escherichia coli ATCC25922, Klebsiella pneumoniae ST258 and Acinetobacter baumannii AYE (Table 3). 
Variable levels of potentiation were observed for other antibiotics, with the action of the hydrophobic antibiotic 
erythromycin being improved against E. coli, K. pneumoniae and A. baumannii and nalidixic acid exhibiting 
enhanced activity against P. aeruginosa and K. pneumoniae. Negligible potentiation was observed against the 
test organisms for chloramphenicol. 
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Table 3. Antibiotic potentiating activity of 3. 
Antibiotic  
Concentration (µM) for potentiationa  
P. ab E. cc K. pd A. be 
Doxycycline 12.5 6.25 6.25 25 
Erythromycin 200 50 50 25 
Chloramphenicol >200 >200 200 >200 
Nalidixic acid 50 >200 25 200 
a Concentration (µM) of compound required to restore antibiotic activity at 2 µg/mL concentration of antibiotic. 
b Pseudomonas aeruginosa ATCC27853. Positive controls were doxycycline (MIC 50 μM), erythromycin (MIC >200 µM), 
chloramphenicol (MIC >200 µM) and nalidixic acid (MIC >200 μM). Values presented are the mean (n = 3). 
c Escherichia coli ATCC25922. Positive controls were doxycycline (MIC 25 μM) erythromycin (MIC >200 µM), 
chloramphenicol (MIC >200 µM) and nalidixic acid (MIC >200 μM). Values presented are the mean (n = 3). 
d Klebsiella pneumoniae ST258. Positive controls were doxycycline (MIC 25 μM) erythromycin (MIC >200 µM), 
chloramphenicol (MIC 50 µM) and nalidixic acid (MIC 100 μM). Values presented are the mean (n = 3). 
e Acinetobacter baumannii AYE. Positive controls were doxycycline (MIC 12.5 μM) erythromycin (MIC 200 µM), 
chloramphenicol (MIC >200 µM) and nalidixic acid (MIC >200 μM). Values presented are the mean (n = 3). 
 
The cytotoxicity of compounds 3–15 were evaluated against rat skeletal muscle (L6) and human embryonic 
kidney (HEK-293) cell lines, finding moderate cytotoxicity to both cell lines for all of the polyamine derivatives 
3–9 with IC50 values ranging from 1.55 to 17.1 µM (Table 4). The other compounds in the library were only 
weakly cytotoxic. Human red blood cell haemolytic activity was observed for three (5, 8, 9) of the seven 
polyamines, with 3, 4, 6, 7 having HC10 values typically greater than 32 M. 
 
Table 4. Cytotoxicity and haemolytic activities of indolglyoxylamide derivatives 3–15. 
Compound 
Cytotoxicity 
HC10 (µM)
c 
L6a IC50 (µM) HEK-293
b CC50 (µM) 
3 7.7
d 5.06 >34e 
4 8.7 2.32 >50
 e 
5 5.7 17.1 18.00 
6 4.4 10.6 >33
 e 
7 5.6 6.20 >32
 e 
8 12.4 6.03 7.88 
9 1.6 9.72 2.18 
10 89.3 >52
 e n.d. f 
11 >150 >54
 e n.d. 
12 89.1 >46
 e n.d. 
13 75.4 >44
 e n.d. 
14 99.5 >95
 e n.d. 
15 156.9 >84
 e n.d. 
a L6 rat skeletal myoblast cell line with podophyllotoxin as the positive control (IC50 0.018 µM) and values presented as the 
mean (n = 2).  
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b Concentration of compound at 50% cytotoxicity on HEK293 human embryonic kidney cells and values presented as the 
mean (n = 2). 
c Concentration of compound at 10% haemolytic activity on human red blood cells and values presented as the mean (n = 2). 
d Data taken from Wang et al.13 
e Not active at a single dose test of 32 µg/mL. 
f Not determined. 
 
Lipophilic polyamines are noted for their abilities to increase the permeability of bacterial outer membranes, 
with examples including squalamine,
10
 ianthelliformisamine derivatives,
7
 claramine,
16
 and 
naphthylacetylspermine.
17
 An increase in membrane permeability is linked to bacterial cell death (antimicrobial 
activity) and also with the ability to enhance the action of hydrophobic antibiotics.
17
  
The effect of 3 on bacterial membrane integrity of Gram-negative (Pseudomonas aeruginosa PAO1) and Gram-
positive (Staphylococcus aureus) bacteria was assessed by measuring intracellular ATP release using a 
bioluminescence method. Brief (1 min) exposure of cells to 3 led to dose-dependent increases in extracellular 
ATP. In the case of P. aeruginosa (Fig. 3), rapid ATP leakage was detected with a higher response than that 
observed for the positive control, surfactant cetyltrimethylammonium bromide (CTAB), while the polyamine 
negative control, spermine, showed no such effect. Experiments using 3 (at ~10 µg/mL) and an increased 
concentration of CTAB (1%) revealed that 10% of the intracellular ATP was released after only a few seconds 
of contact (data not shown) suggesting a rapid disruption of the membrane barrier of the Gram-negative 
bacterium. 
 
Fig. 3. Dose-dependent ATP release in P. aeruginosa (PAO1) exhibited by 3. 
 
Similar studies were conducted against the Gram-positive S. aureus strain where bromide 3 also caused rapid 
ATP leakage in a dose dependent manner (Fig. 4) albeit at a lower rate than the positive control, CTAB. 
Between them, the ATP leakage assays established that 3 can disrupt the integrity of bacterial membranes.   
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Fig. 4. Dose-dependent ATP release in S. aureus exhibited by 3. 
 
The noted ability of 3 to enhance the antibiotic action of doxycycline towards a range of Gram negative bacteria 
(Table 3) may arise from the polyamines ability to inhibit drug efflux systems. In particular, efflux pumps are 
often associated with the inherent resistance of P. aeruginosa.
18,19
 In order to actively pump foreign molecules 
including antibiotics against their concentration gradient, an energy source such as a proton concentration 
gradient is required. Perturbation of the inner membrane through depolarisation causes loss of the proton 
concentration gradient resulting in the loss of the energy needed to efflux foreign compounds.
18,19 
To better 
understand whether 3 can act as a disruptor of the transmembrane potential, a real-time efflux assay was 
utilised.
20
 This assay makes use of the membrane-potential-sensitive probe DiSC3(5), which when preloaded 
into bacteria, concentrates in the inner membrane and quenches its own fluorescence. Upon membrane 
depolarisation, the dye is released and an increase in fluorescence (measured in relative fluorescence units) is 
observed. In a single-dose (10.4 M) 15 min incubation experiment, strong depolarization was observed against 
both P. aeruginosa PAO1 and S. aureus ATCC25923 with a particularly strong response from the Gram-
positive strain (Fig. 5). Negligible effect was observed for the negative control spermine. 
 
Fig. 5. Membrane depolarisation of P. aeruginosa (PAO1) and S. aureus by 3 at a single dose of 10.4 µM as measured using 
DiSC3(5) fluorescent dye release.  
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Closer examination of the membrane depolarization of S. aureus exhibited by 3 identified a dose-dependent 
response, with a rapid and strong in fluorescence (RFU), as also observed for the positive control, squalamine 
(Fig. 6). 
 
Fig. 6. Dose-dependent membrane depolarisation of S. aureus exhibited by 3. 
 
Taken together these results suggest that the intrinsic antimicrobial activity of 3 may arise from rapid disruption 
of cell membrane integrity, resulting in the loss of cell wall rigidity, leading to cell death while the antibiotic 
potentiating ability may arise from indirect efflux pump inhibition via depolarisation of the membrane.   
 
4. Conclusion 
Our initial screening identified 6-bromoindolglyoxylamides 3 and 4 as modest to moderately active 
antimicrobial agents with 3 also exhibiting the ability to enhance the antibiotic action of doxycycline and 
erythromycin towards a number of the Gram-negative bacteria including Pseudomonas aeruginosa, Escherichia 
coli and Acinetobacter baumannii. Preliminary exploration of the findings identified that longer polyamine 
chain analogues could exhibit more pronounced antimicrobial properties, and this peaked with the polyamine 
PA3-8-3 core for antibacterial activity and for the PA3-10-3 core for antifungal properties. Analogues that 
lacked a polyamine core were essentially devoid of antimicrobial activity. Antibiotic potentiating activity 
required the presence of a polyamine scaffold, with 3, 5 and 8 being the most potent enhancers. Mechanism of 
action studies identified 3 as being able to disrupt the integrity of, and depolarize, bacterial membranes. The 
therapeutic potential of this class of compound is however limited by the observation of cytotoxicity, 
overcoming which is the focus of current studies.  
  
5. Experimental 
5.1. General remarks 
Infrared spectra were recorded on a Perkin-Elmer spectrometer 100 Fourier Transform infrared spectrometer 
equipped with a universal ATR accessory. Mass spectra were acquired on a Bruker micrOTOF Q II 
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spectrometer. 
1
H and 
13
C NMR spectra were recorded at 298 K on a Bruker AVANCE 400 spectrometer at 400 
and 100 MHz, respectively using standard pulse sequences. Proto-deutero solvent signals were used as internal 
references (DMSO-d6: δH 2.50, δC 39.52; CDCl3: δH 7.26, δC 77.16). For 
1
H NMR, the data are quoted as 
position (δ), relative integral, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = 
broad), coupling constant (J, Hz), and assignment to the atom. The 
13C NMR data are quoted as position (δ), and 
assignment to the atom. Silica gel column chromatography was carried out using Davisil silica gel (40–60 μm) 
or Merck silica gel (15–40 μm). Column chromatography was also conducted on Merck Diol bonded silica (40–
63 µm). Gel filtration flash chromatography was carried out on Sephadex LH-20 (Pharmacia). Thin layer 
chromatography was conducted on Merck DC-plastikfolien Kieselgel 60 F254 plates. All solvents used were of 
analytical grade or better and/or purified according to standard procedures. Chemical reagents used were 
purchased from standard chemical suppliers and used as purchased. All samples were determined to >95% 
purity. Compounds 3,
13
 4,
13
 7,
13
 16,
15
 17,
11
 di-tert-butyl hexane-1,6-diylbis((3-aminopropyl)carbamate),
14
 di-
tert-butyl heptane-1,7-diylbis((3-aminopropyl)carbamate),
14
 di-tert-butyl decane-1,10-diylbis((3-
aminopropyl)carbamate)
14
 and di-tert-butyl dodecane-1,12-diylbis((3-aminopropyl)carbamate)
14
 were 
synthesised by literature procedures.
  
 
5.2. Synthesis of compounds 
 
5.2.1. General procedure for the preparation of compounds 5, 6, 8 and 9.  
A two-step sequence was used for the preparation of these target compounds. In the first step, reaction of 2-(6-
bromo-1H-indol-3-yl)-2-oxoacetyl chloride 16
15
 (2 eq.) and the appropriate Boc protected polyamine
14
 (1 eq.) in 
DMF (1 mL) with DIPEA (6 eq.) were stirred for 48 h before solvent removal under reduced pressure. The 
crude reaction product was then subjected to Boc deprotection without any purification. A solution of crude tert-
butyl-carboxylate derivative in CH2Cl2 (2 mL) and TFA (0.2 mL) was stirred at room temperature under N2 for 
2 h followed by solvent removal under reduced pressure. The reaction product was purified using C8 reversed-
phase column chromatography [0%–50% MeOH/H2O (0.05% TFA)] to afford derivatives 5, 6, 8 and 9 as their 
di-TFA salt. 
 
5.2.1.1. N
1
,N
6
-Bis(3-(2-(6-bromo-1H-indol-3-yl)-2-oxoacetamido)propyl)hexane-1,6-diaminium 2,2,2-
trifluoroacetate (5) 
Following the general procedure, to a solution of 2-(6-bromo-1H-indol-3-yl)-2-oxoacetyl chloride
15
 (0.072 g, 
0.25 mmol) in DMF (2 mL) was added DIPEA (0.13 mL, 0.74 mmol) and di-tert-butyl hexane-1,6-diylbis((3-
aminopropyl)carbamate)
14
 (0.053 g, 0.12 mmol). The reaction mixture was stirred at room temperature for 48 h 
under N2. The crude product was dissolved in CH2Cl2 (20 mL), washed with brine (2 x 20 mL) and the solvent 
removed in vacuo to afford di-tert-butyl hexane-1,6-diylbis((3-(2-(6-bromo-1H-indol-3-yl)-2-
oxoacetamido)propyl)carbamate) as an orange oil (0.017 g, 15%). A sub-sample of this material (0.008 g, 0.008 
mmol) was then deprotected by reaction with TFA (0.2 mL) in CH2Cl2 (2 mL) to give a crude product that was 
 12 
 
purified by C8 reversed-phase column chromatography [0%–50% MeOH (+0.05% TFA)/H2O] to afford 5 as a 
pale yellow oil (0.003 g, 33%).  
IR (ATR) vmax 3439, 2981, 1675, 1629, 1442, 1201, 1132, 1024, 1000, 725, 799 cm
-1
; 
1
H NMR (DMSO-d6, 400 
MHz) δ 12.35 (2H, br s, NH-1, NH-1'), 8.92 (2H, t, J = 5.6 Hz, NH-10, NH-10'), 8.79 (2H, s, H-2, H-2'), 8.47–
8.35 (4H, m, NH2-14, NH2-14'), 8.16 (2H, d, J = 8.6 Hz, H-4, H-4'), 7.76 (2H, d, J = 1.5 Hz, H-7, H-7'), 7.42 
(2H, dd, J = 8.6, 1.5 Hz, H-5, H-5 '), 3.33–3.28 (4H, m, H2-11, H2-11'), 3.00–2.92 (4H, m, H2-13, H2-13'), 2.92–
2.86 (4H, m, H2-15, H2-15'), 1.89–1.83 (4H, m, H2-12, H2-12'), 1.60–1.54 (4H, m, H2-16, H2-16'), 1.33–1.30 
(4H, m, H2-17, H2-17'); 
13
C NMR (DMSO-d6, 100 MHz) δ 181.8 (C-8, C-8'), 163.4 (C-9, C-9'), 139.3 (C-2, C-
2'), 137.2 (C-7a, C-7a'), 125.5 (C-5, C-5'), 125.2 (C-3a, C-3a'), 122.9 (C-4, C-4'), 116.0 (C-6, C-6'), 115.4 (C-7, 
C-7'), 112.0 (C-3, C-3'), 46.7 (C-15, C-15'), 44.7 (C-13, C-13'), 35.8 (C-11, C-11'), 25.7 (C-12, C-12'), 25.5 (C-
17, C-17'), 25.4 (C-16, C-16'); (+)-HRESIMS [M+H]
+ 
m/z 729.1416 (calcd for C32H39
79
Br2N6O4, 729.1394), 
731.1395 (calcd for C32H39
79
Br
81
BrN6O4, 731.1376), 733.1383 (calcd for C32H39
81
Br2N6O4, 733.1364). 
 
5.2.1.2.  N
1
,N
7
-Bis(3-(2-(6-bromo-1H-indol-3-yl)-2-oxoacetamido)propyl)heptane-1,7-diaminium 2,2,2-
trifluoroacetate (6) 
Following the general procedure, to a solution of 2-(6-bromo-1H-indol-3-yl)-2-oxoacetyl chloride
15
 (0.072 g, 
0.25 mmol) in DMF (2 mL) was added DIPEA (0.13 mL, 0.74 mmol) and di-tert-butyl heptane-1,7-diylbis((3-
aminopropyl)carbamate)
14
 (0.055 g, 0.12 mmol). The reaction mixture was stirred at room temperature for 48 h 
under N2. The crude product was dissolved in CH2Cl2 (20 mL), washed with brine (2 x 20 mL) and the solvent 
removed in vacuo to afford di-tert-butyl heptane-1,7-diylbis((3-(2-(6-bromo-1H-indol-3-yl)-2-
oxoacetamido)propyl)carbamate) as a red-orange oil (0.021 g, 18%). A sub-sample of this material (0.020 g, 
0.022 mmol) was then deprotected by reaction with TFA (0.2 mL) in CH2Cl2 (2 mL) to give a crude product that 
was purified by C8 reversed-phase column chromatography [0%–50% MeOH (+0.05% TFA)/H2O] to afford 6 as 
a pale yellow oil (0.006 g, 29%).  
IR (ATR) vmax 3349, 2947, 2834, 1552, 1450, 1416, 1204, 1113 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz) δ 12.38 
(2H, br s, NH-1, NH-1'), 8.91 (2H, t, J = 6.1 Hz, NH-10, NH-10'), 8.78 (2H, s, H-2, H-2'), 8.47–8.44 (4H, m, 
NH2-14, NH2-14'), 8.15 (2H, d, J = 8.5 Hz, H-4, H-4'), 7.75 (2H, d, J = 1.6 Hz, H-7, H-7'), 7.41 (2H, dd, J = 8.5, 
1.6 Hz, H-5, H-5'), 3.31–3.28 (4H, m, H2-11, H2-11'), 2.96–2.88 (8H, m, H2-13, H2-13', H2-15, H2-15'), 1.88–
1.83 (4H, m, H2-12, H2-12'), 1.58–1.54 (4H, m, H2-16, H2-16'), 1.28–1.24 (6H, m, H2-17, H2-17', H2-18); 
13
C 
NMR (DMSO-d6, 100 MHz) δ 181.8 (C-8, C-8'), 163.4 (C-9, C-9'), 139.3 (C-2, C-2'), 137.2 (C-7a, C-7a'), 125.4 
(C-5, C-5'), 125.2 (C-3a, C-3a'), 122.9 (C-4, C-4'), 116.0 (C-6, C-6'), 115.4 (C-7, C-7'), 112.0 (C-3, C-3'), 46.7 
(C-15, C-15'), 44.7 (C-13, C-13'), 35.8 (C-11, C-11'), 28.0 (C-18), 25.8 (C-12, C-12'), 25.7 (C-17, C-17'), 25.4 
(C-16, C-16'); (+)-HRESIMS [M+H]
+ 
m/z 743.1534 (calcd for C33H41
79
Br2N6O4, 743.1551), 745.1517 (calcd for 
C33H41
79
Br
81
BrN6O4, 745.1533), 747.1504 (calcd for C33H41
81
Br2N6O4, 747.1521). 
 
5.2.1.3.  N
1
,N
10
-bis(3-(2-(6-bromo-1H-indol-3-yl)-2-oxoacetamido)propyl)decane-1,10-diaminium 2,2,2-
trifluoroacetate (8) 
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Following the general procedure, to a solution of 2-(6-bromo-1H-indol-3-yl)-2-oxoacetyl chloride
15
 (0.076 g, 
0.27 mmol) in DMF (2 mL) was added DIPEA (0.14 mL, 0.80 mmol) and di-tert-butyl decane-1,10-diylbis((3-
aminopropyl)carbamate)
14
 (0.063 g, 0.13 mmol). The reaction mixture was stirred at room temperature for 48 h 
under N2. The crude product was dissolved in CH2Cl2 (20 mL), washed with brine (2 x 20 mL) and the solvent 
removed in vacuo to afford di-tert-butyl decane-1,10-diylbis((3-(2-(6-bromo-1H-indol-3-yl)-2-
oxoacetamido)propyl)carbamate) as a dark orange oil (0.42 g, 33%). A sub-sample of this material (0.014 g, 
0.014 mmol) was then deprotected by reaction with TFA (0.2 mL) in CH2Cl2 (2 mL) to give a crude product that 
was purified by C8 reversed-phase column chromatography [0%–50% MeOH (+0.05% TFA)/H2O] to afford 8 as 
a pale yellow oil (0.006 g, 55%).  
IR (ATR) vmax 3394, 2259, 1654, 1024, 993, 825, 762 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz) δ 12.46 (2H, br s, 
NH-1, NH-1'), 8.98 (2H, t, J = 6.2 Hz, NH-10, NH-10'), 8.84 (2H, d, J = 3.1 Hz, H-2, H-2'), 8.79 (4H, br s, NH2-
14, NH2-14'), 8.22 (2H, d, J = 8.5 Hz, H-4, H-4'), 7.82 (2H, d, J = 2.0 Hz, H-7, H-7'), 7.47 (2H, dd, J = 8.5, 2.0 
Hz, H-5, H-5'), 3.36 (4H, dt, J = 6.4, 6.2 Hz, H2-11, H2-11'), 3.06–2.91 (8H, m, H2-13, H2-13', H2-15, H2-15'), 
1.94–1.84 (4H, m, H2-12, H2-12'), 1.65–1.58 (4H, m, H2-16, H2-16'), 1.36–1.29 (12H, m, H2-17, H2-17', H2-18, 
H2-18', H2-19, H2-19'); 
13
C NMR (DMSO-d6, 100 MHz) δ 181.8 (C-8, C-8'), 163.5 (C-9, C-9'), 138.8 (C-2, C-
2'), 137.2 (C-7a, C-7a'), 125.8 (C-3a, C-3a'), 125.4 (C-5, C-5'), 122.9 (C-4, C-4'), 117.9 (C-6, C-6'), 115.3 (C-7, 
C-7'), 113.8 (C-3, C-3'), 46.8 (C-15, C-15'), 44.7 (C-13, C-13'), 35.8 (C-11, C-11'), 28.7 (C-18, C-18'), 28.5 (C-
19, C-19'), 25.9 (C-12, C-12'), 25.6 (C-17, C-17'), 25.4 (C-16, C-16'); (+)-HRESIMS [M+H]
+ 
m/z 785.2031 
(calcd for C36H47
79
Br2N6O4, 785.2020), 787.2060 (calcd for C36H47
79
Br
81
BrN6O4, 787.2003), 789.2015 (calcd for 
C36H47
81
Br2N6O4, 789.1992). 
 
5.2.1.4.  N
1
,N
12
-bis(3-(2-(6-bromo-1H-indol-3-yl)-2-oxoacetamido)propyl)dodecane-1,12-diaminium 2,2,2-
trifluoroacetate (9) 
Following the general procedure, to a solution of 2-(6-bromo-1H-indol-3-yl)-2-oxoacetyl chloride
15
 (0.078 g, 
0.27 mmol) in DMF (2 mL) was added DIPEA (0.14 mL, 0.82 mmol) and di-tert-butyl dodecane-1,12-
diylbis((3-aminopropyl)carbamate)
14
 (0.070 g, 0.14 mmol). The reaction mixture was stirred at room 
temperature for 48 h under N2. The crude product was dissolved in CH2Cl2 (20 mL), washed with brine (2 x 20 
mL) and the solvent removed in vacuo to afford di-tert-butyl dodecane-1,12-diylbis((3-(2-(6-bromo-1H-indol-3-
yl)-2-oxoacetamido)propyl)carbamate) as a dark orange oil (0.041 g, 28.9%). A sub-sample of this material 
(0.019 g, 0.019 mmol) was then deprotected by reaction with TFA (0.2 mL) in CH2Cl2 (2 mL) to give a crude 
product that was purified by C8 reversed-phase column chromatography [0%–50% MeOH (+0.05% TFA)/H2O] 
to afford 9 as a pale yellow oil (0.016 g, quantitative).  
IR (ATR) vmax 3350, 2928, 2840, 1678, 1634, 1503, 1441, 1203, 1137, 1032, 799, 722 cm
-1
; 
1
H NMR (DMSO-
d6, 400 MHz) δ 12.47 (2H, br s, NH-1, NH-1'), 8.91 (2H, t, J = 6.0 Hz, NH-10, NH-10'), 8.77 (2H, d, J = 2.8 Hz, 
H-2, H-2'), 8.56–8.54 (4H, m, NH2-14, NH2-14'), 8.15 (2H, d, J = 8.5 Hz, H-4, H-4'), 7.75 (2H, d, J = 1.3 Hz, H-
7, H-7'), 7.40 (2H, dd, J = 8.5, 1.3 Hz, H-5, H-5'), 3.32–3.27 (4H, m, H2-11, H2-11'), 2.93–2.89 (8H, m, H2-13, 
H2-13', H2-15, H2-15'), 1.87–1.83 (4H, m, H2-12, H2-12'), 1.55–1.53 (4H, m, H2-16, H2-16'), 1.27–1.21 (16H, m, 
H2-17, H2-17', H2-18, H2-18', H2-19, H2-19', H2-20, H2-20'); 
13
C NMR (DMSO-d6, 100 MHz) δ 181.8 (C-8, C-
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8'), 163.5 (C-9, C-9'), 139.3 (C-2, C-2'), 137.2 (C-7a, C-7a'), 125.4 (C-3a, C-3a'), 125.3 (C-5, C-5'), 122.9 (C-4, 
C-4'), 116.0 (C-6, C-6'), 115.4 (C-7, C-7'), 112.1 (C-3, C-3'), 46.8 (C-15, C-15'), 44.7 (C-13, C-13'), 35.8 (C-11, 
C-11'), 28.9 (C-18, C-18'), 28.8 (C-19, C-19'), 28.5 (C-20, C-20'), 25.9 (C-12, C-12'), 25.6 (C-17, C-17'), 25.5 
(C-16, C-16'); (+)-HRESIMS [M+H]
+ 
m/z 813.2346 (calcd for C38H51
79
Br2N6O4, 813.2333), 815.2331 (calcd for 
C38H51
79
Br
81
BrN6O4, 815.2317), 817.2316 (calcd for C38H51
81
Br2N6O4, 817.2306). 
 
5.2.2 General procedure for the preparation of analogues 10–15. 
To a stirred solution of 2-(6-bromo-1H-indol-3-yl)-oxoacetic acid (17)
11
 (1 eq.) and diamine (1 eq.) in DMF (2 
mL) was added PyBOP (1 eq.) and triethylamine (3 eq.). The reaction mixture was stirred for 24 h at room 
temperature under N2. To the crude reaction product was added CH2Cl2 (30 mL) and the organic layer washed 
with aq. K2CO3 (1%, 2 x 30 mL) followed by water (2 x 30 mL). The organic extract was concentrated under 
reduced pressure and subjected to purification (as described below) to afford the target compound. 
 
5.2.2.1.  2-(6-Bromo-1H-indol-3-yl)-N-(3-((2-(2-(6-bromo-1H-indol-3-yl)-2-
oxoacetamido)ethyl)amino)propyl)-2-oxoacetamide (10) 
Following the general procedure, 17
11
 (0.087 g, 0.324 mmol) was reacted with aminoethyl-1,3-propandiamine 
(0.020 mL, 0.162 mmol), PyBOP (0.169 g, 0.324 mmol) and triethylamine (0.135 mL, 0.972 mmol) in DMF for 
24 h. The crude reaction product was concentrated under reduced pressure and washed with CH2Cl2 followed by 
MeOH/water (1:4) to afford 10 as a yellow solid (0.058 g, 58%). 
Rt 10.82 mins; m.p. > 250 °C; IR (ATR) vmax 3287, 3178, 2953, 1655, 1597, 1505, 1234, 658 cm
-1
; 
1
H NMR 
(DMSO-d6, 400 MHz) δ 12.40 (2H, br s, NH-1, NH-26), 8.94 (1H, t, J = 5.8 Hz, NH-17), 8.92 (1H, t, J = 6.3 
Hz, NH-10), 8.83 (1H, s, H-2/H-25), 8.78 (1H, s, H-2/H-25), 8.15 (1H, d, J = 8.5 Hz, H-4/H-23), 8.14 (1H, d, J 
= 8.5 Hz, H-4/H-23), 7.75 (1H, d, J = 1.8 Hz, H-7/H-20), 7.74 (1H, d, J = 8.5 Hz, H-7/H-20), 7.40 (1H, dd, J = 
8.5, 1.8 Hz, H-5/H-22), 7.39 (1H, dd, J = 8.5, 1.8 Hz, H-5/H-22), 3.57–3.52 (2H, m, H2-11), 3.31–3.28 (2H, m, 
H2-16), 3.10 (2H, t, J = 6.0 Hz, H2-12), 2.97 (2H, t, J = 7.4 Hz, H2-14), 1.92–1.83 (2H, m, H2-15), NH-13 not 
observed; 
13
C NMR (DMSO-d6, 100 MHz) δ 181.9 (C-8/C-19), 181.1 (C-8/C-19), 163.44 (C-9/C-18), 163.36 
(C-9/C-18), 139.4 (C-2/C-25), 139.2 (C-2/C-25), 137.21 (C-7a/C-26a), 137.16 (C-7a/C-26a), 125.5 (C-5, C-22), 
125.2 (C-3a, C-23a), 122.9 (C-4, C-23), 116.0 (C-6, C-21), 115.4 (C-7, C-20), 112.03 (C-3/C-24), 111.96 (C-
3/C-24), 46.1 (C-12), 44.8 (C-14), 35.9 (C-11), 35.3 (C-16), 25.8 (C-15); (+)-HIRESIMS m/z 616.0168 [M+H]
+
 
(calcd for C25H24Br2N5O4, 616.0190). 
 
5.2.2.2.  N,N'-(Butane-1,4-diyl)bis(2-(6-bromo-1H-indol-3-yl)-2-oxoacetamide) (11) 
Following the general procedure, 17
11
 (0.091 g, 0.340 mmol) was reacted with 1,4-diaminobutane (0.015 g, 
0.170 mmol), PyBOP (0.177 g, 0.340 mmol) and triethylamine (0.142 mL, 1.02 mmol) in DMF for 24 h. The 
crude reaction product was concentrated under reduced pressure and washed with MeOH/water (4:1) to afford 
11 as a brown solid (0.058 g, 58%). 
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Rt 8.06 mins; m.p. > 250 °C; IR (ATR) vmax 3241, 2931, 2872, 1652, 1605, 1416, 1239, 661 cm
-1
; 
1
H NMR 
(DMSO-d6, 400 MHz) δ 12.26 (2H, d, J = 2.0 Hz, NH-1, NH-1ʹ), 8.76 (2H, t, J = 5.6 Hz, NH-10, NH-10ʹ), 8.76 
(2H, d, J = 3.0 Hz, H-2, H-2ʹ), 8.14 (2H, d, J = 8.5 Hz, H-4, H-4ʹ), 7.72 (2H, d, J = 1.3 Hz, H-7, H-7ʹ), 7.39 (2H, 
dd, J = 8.5, 1.3 Hz, H-5, H-5ʹ), 3.27–3.21 (4H, m, H2-11, H2-11ʹ), 1.57–1.52 (4H, m, H2-12, H2-12ʹ); 
13
C NMR 
(DMSO-d6, 100 MHz) δ 182.4 (C-8, C-8ʹ), 163.3 (C-9, C-9ʹ), 139.2 (C-2, C-2ʹ), 137.2 (C-7a, C-7aʹ), 125.3 (C-5, 
C-5ʹ), 125.2 (C-3a, C-3aʹ), 122.9 (C-4, C-4ʹ), 115.9 (C-6, C-6ʹ), 115.2 (C-7, C-7ʹ), 112.1 (C-3, C-3ʹ), 38.2 (C-11, 
C-11ʹ), 26.3 (C-12, C-12ʹ); (+)-HIRESIMS m/z 608.9714 [M+Na]+ (calcd for C24H20Br2N4NaO4, 608.9744). 
 
5.2.2.3.  N,N'-(Dodecane-1,12-diyl)bis(2-(6-bromo-1H-indol-3-yl)-2-oxoacetamide) (12) 
Following the general procedure, 17
11
 (0.077 g, 0.286 mmol) was reacted with 1,12-diaminododecane (0.029 g, 
0.143 mmol), PyBOP (0.149 g, 0.286 mmol) and triethylamine (0.119 mL, 0.857 mmol) in DMF for 24 h. The 
crude reaction product was concentrated under reduced pressure and washed with MeOH/water (4:1) to afford 
12 as an off-white solid (0.080 g, 80%). 
Rt 7.98 mins; m.p. > 250 °C; IR (ATR) vmax 3304, 3234, 2921, 1604, 1505, 1421, 1128, 799 cm
-1
; 
1
H NMR 
(DMSO-d6, 400 MHz) δ 12.26 (2H, br s, NH-1, NH-1ʹ), 8.75 (2H, s, H-2, H-2ʹ), 8.70 (2H, t, J = 5.9 Hz, NH-10, 
NH-10ʹ), 8.14 (2H, d, J = 8.5 Hz, H-4, H-4ʹ), 7.73 (2H, d, J = 1.0 Hz, H-7, H-7ʹ), 7.39 (2H, dd, J = 8.5, 1.0 Hz, 
H-5, H-5ʹ), 3.22–3.15 (4H, m, H2-11, H2-11ʹ), 1.53–1.45 (4H, m, H2-12, H2-12ʹ), 1.27–1.22 (16H, m, H2-13, H2-
14, H2-15, H2-16, H2-13ʹ, H2-14ʹ, H2-15ʹ, H2-16ʹ); 
13
C NMR (DMSO-d6, 100 MHz) δ 182.4 (C-8, C-8ʹ), 163.2 
(C-9, C-9ʹ), 139.2 (C-2, C-2ʹ), 137.2 (C-7a, C-7aʹ), 125.3 (C-5, C-5ʹ), 125.2 (C-3a, C-3aʹ), 122.9 (C-4, C-4ʹ), 
115.9 (C-6, C-6ʹ), 115.3 (C-7, C-7ʹ), 112.1 (C-3, C-3ʹ), 38.5 (C-11, C-11ʹ), 29.0 (C-12/C-13/C-14/C-15/C-16/C-
12ʹ/C-13ʹ/C-14ʹ/C-15ʹ/C-16ʹ), 28.73 (C-12/C-13/C-14/C-15/C-16/C-12ʹ/C-13ʹ/C-14ʹ/C-15ʹ/C-16ʹ), 28.68 (C-
12/C-13/C-14/C-15/C-16/C-12ʹ/C-13ʹ/C-14ʹ/C-15ʹ/C-16ʹ), 26.4 (C-12/C-13/C-14/C-15/C-16/C-12ʹ/C-13ʹ/C-
14ʹ/C-15ʹ/C-16ʹ); (+)-HIRESIMS m/z 721.0973 [M+Na]+ (calcd for C32H36Br2N4NaO4, 721.0996). 
 
5.2.2.4.  N,Nʹ-(((Oxybis(ethane-2,1-diyl))bis(oxy))bis(propane-3,1-diyl)) bis(2-(6-bromo-1H-indol-3-yl)-2-
oxoacetamide) (13) 
Following the general procedure, 17
11
 (0.075 g, 0.278 mmol) was reacted with 4,7,10-trioxa-1,13-
tridecanediamine (0.030 mL, 0.139 mmol), PyBOP (0.145 g, 0.278 mmol) and triethylamine (0.116 mL, 0.833 
mmol) in DMF for 24 h. Solvent was removed under reduced pressure and the crude reaction product was 
subjected to purification by a combination of silica gel (CH2Cl2/5%MeOH) and Sephadex LH20 (MeOH) 
column chromatography, to afford 13 as a white solid (0.024 g, 24%). 
Rf (CH2Cl2/MeOH, 9:1) 0.51; m.p. 189.6–191.2 °C; IR (ATR) vmax 3216, 2922, 2866, 1655, 1598, 1503, 1134, 
1107, 742, 659 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz) δ 12.23 (2H, br s, NH-1, NH-1ʹ), 8.76 (2H, s, H-2, H-2ʹ), 
8.71 (2H, t, J = 5.9 Hz, NH-10, NH-10ʹ), 8.14 (2H, d, J = 8.5 Hz, H-4, H-4ʹ), 7.72 (2H, d, J = 1.4 Hz, H-7, H-
7ʹ), 7.39 (2H, dd, J = 8.5, 1.4 Hz, H-5, H-5ʹ), 3.56–3.47 (8H, m, H2-14, H2-15, H2-14ʹ, H2-15ʹ), 3.44 (4H, t, J = 
6.1 Hz, H3-13, H3-13ʹ), 3.29–3.24 (4H, m, H2-11, H2-11ʹ), 1.78–1.70 (4H, m, H2-12, H2-12ʹ); 
13
C NMR (DMSO-
d6, 100 MHz) δ 182.3 (C-8, C-8ʹ), 163.2 (C-9, C-9ʹ), 139.2 (C-2, C-2ʹ), 137.2 (C-7a, C-7aʹ), 125.3 (C-5, C-5ʹ), 
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125.2 (C-3a, C-3aʹ), 122.9 (C-4, C-4ʹ), 115.9 (C-6, C-6ʹ), 115.2 (C-7, C-7ʹ), 112.1 (C-3, C-3ʹ), 69.8 (C-14/C-
15/C-14ʹ/C-15ʹ), 69.6 (C-14/C-15/C-14ʹ/C-15ʹ), 68.3 (C-13, C-13ʹ), 36.2 (C-11, C-11ʹ), 29.0 (C-12, C-12ʹ); (+)-
HIRESIMS m/z 741.0533 [M+Na]
+
 (calcd for C30H32Br2N4NaO7, 741.0530). 
 
5.2.2.5.  2-(6-Bromo-1H-indol-3-yl)-N-(2-(dimethylamino)ethyl)-2-oxoacetamide (14) 
Following the general procedure, 17
11
 (0.079 g, 0.296 mmol) was reacted with N,N-dimethylethylenediamine 
(0.032 mL, 0.296 mmol), PyBOP (0.154 g, 0.296 mmol) and triethylamine (0.124 mL, 0.887 mmol) in DMF for 
24 h. Purification by diol-bonded silica gel column chromatography (CH2Cl2/3% MeOH) afforded 14 as a white 
solid (0.041 g, 41%). 
Rf (CH2Cl2/MeOH, 9:1) 0.11; m.p. 209.1–210.5 °C; IR (ATR) vmax 3345, 3129, 2779, 1615, 1534, 1482, 1231, 
816, 681 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz) δ 12.28 (1H, br s, NH-1), 8.80 (1H, s, H-2), 8.56 (1H, t, J = 5.8 
Hz, NH-10), 8.14 (1H, d, J = 8.3 Hz, H-4), 7.73 (1H, d, J = 1.8 Hz, H-7), 7.40 (1H, dd, J = 8.3, 1.8 Hz, H-5), 
3.34–3.27 (2H, m, H2-11), 2.39 (2H, t, J = 6.7 Hz, H2-12), 2.18 (6H, s, 2H3-13); 
13
C NMR (DMSO-d6, 100 
MHz) δ 182.1 (C-8), 163.0 (C-9), 139.4 (C-2), 137.2 (C-7a), 125.4 (C-5), 125.2 (C-3a), 122.9 (C-4), 115.9 (C-
6), 115.3 (C-7), 112.1 (C-3), 57.6 (C-12), 45.1 (C-13), 36.6 (C-11); (+)-HIRESIMS m/z 338.0498 [M+H]
+
 
(calcd for C14H16BrN3O2, 338.0499). 
 
5.2.2.6.  2-(6-Bromo-1H-indol-3-yl)-N-(2-morpholinoethyl)-2-oxoacetamide (15) 
Following the general procedure, 17
11
 (0.071 g, 0.263 mmol) was reacted with 2-morpholinoethylamine (0.034 
g, 0.263 mmol), PyBOP (0.137 g, 0.263 mmol) and triethylamine (0.110 mL, 0.789 mmol) in DMF for 24 h. 
Purification by diol-bonded silica gel column chromatography (CH2Cl2/3% MeOH) afforded 15 as a white solid 
(0.046 g, 46%). 
Rf (CH2Cl2/MeOH, 9:1) 0.54; m.p. 200.5–201.4 °C; IR (ATR) vmax 3304, 3255, 2818, 1659, 1598, 1504, 1110, 
661 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 9.04 (1H, d, J = 3.0 Hz, H-2), 9.03 (1H, br s, NH-1), 8.29 (1H, d, J = 
8.7 Hz, H-4), 7.87 (1H, t, J = 5.0 Hz, NH-10), 7.60 (1H, d, J = 1.6 Hz, H-7), 7.44 (1H, dd, J = 8.7, 1.6 Hz, H-5), 
3.75 (4H, t, J = 4.7 Hz, 2H2-14), 3.51–3.46 (2H, m, H2-11), 2.59 (2H, t, J = 6.1 Hz, H2-12), 2.53–2.49 (4H, m, 
2H2-13); 
13
C NMR (CDCl3, 100 MHz) δ 180.9 (C-8), 162.3 (C-9), 138.4 (C-2), 136.6 (C-7a), 126.8 (C-5), 125.7 
(C-3a), 123.9 (C-4), 117.8 (C-6), 114.8 (C-7), 113.6 (C-3), 67.1 (C-14), 57.0 (C-12), 53.6 (C-13), 35.8 (C-11); 
(+)-HIRESIMS m/z 380.0602 [M+H]
+
 (calcd for C16H19BrN3O3, 380.0604). 
 
5.3.  Antimicrobial assays 
5.3.1.  Bacterial strains  
Bacterial strains used in this study were: S. aureus (ATCC25923), S. intermedius (1051997), E. coli 
(ATCC25922) and P. aeruginosa (ATCC27853 and PAO1). Strains were maintained at -80 °C in 15% (v/v) 
glycerol for cryoprotection. Bacteria were routinely grown in Mueller-Hinton (MH) broth at 37 °C. 
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5.3.2.  Antibiotics 
Doxycycline was purchased from TCI Europe and dissolved in water. 
5.3.3.  Antimicrobial evaluation 
The susceptibility of bacterial strains to antibiotics and compounds was determined in microplates using the 
standard broth dilution method in accordance with the recommendations of the Comité de l’AntibioGramme de 
la Société Française de Microbiologie (CA-SFM). Briefly, the minimal inhibitory concentrations (MICs) were 
determined with an inoculum of 10
5
 CFU in 200 µL of MH broth containing two-fold serial dilutions of each 
drug. The MIC was defined as the lowest concentration of drug that completely inhibited visible growth after 
incubation for 18 h at 37 °C. To determine all MICs, the measurements were independently repeated in 
triplicate.  
 
5.4.  Determination of the MICs of antibiotics in the presence of synergising compounds 
Briefly, restoring enhancer concentrations were determined with an inoculum of 5 10
5
 CFU in 200 µL of MH 
broth containing two-fold serial dilutions of each derivative in the presence of doxycycline at 2 µg/mL. The 
lowest concentration of the polyamine adjuvant that completely inhibited visible growth after incubation for 18 
h at 37 °C was determined. These measurements were independently repeated in triplicate.  
 
5.5.  Measurement of ATP efflux 
General procedure illustrated with CTAB (0.1%) 
CTAB solutions (0.1%) were prepared in doubly distilled water at different concentrations. A suspension of 
growing S. aureus (ATCC25923) or P. aeruginosa (PAO1) to be studied in MH broth was prepared and 
incubated at 37 °C. This suspension (90 µL) was added to 10 µL of CTAB solution and vortexed for 1 sec. 
Luciferin-luciferase reagent (Yelen, France; 50 µL) was immediately added to the precedent mix and 
luminescent signal quantified with an Infinite M200 microplate reader (Tecan) for five secs. ATP concentration 
was quantified by internal sample addition. A similar procedure was used for negative control spermine (100 
µg/mL) and for for test compound 3 (4 times the MIC). 
 
5.6.  Membrane depolarisation assays 
Bacteria were grown in MH broth for 24 h at 37 °C and centrifuged at 10000 rpm at 20 °C. The supernatant was 
discarded and the bacteria were washed twice with buffered sucrose solution (250 mM) and magnesium sulfate 
solution (5 mM). The fluorescent dye 3,3′-diethylthiacarbocyanine iodide was added to a final concentration of 
3 µM and allowed to penetrate into bacterial membranes during 1 h of incubation at 37 °C. Bacteria were then 
washed to remove the unbound dye before adding compound at different concentrations. Fluorescence 
measurements were performed using a Jobin Yvon Fluoromax 3 spectrofluorometer with slit widths of 5/5 nm. 
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The maximum RCF was considered to be that recorded with a pure solution of the fluorescent dye in buffer (3 
µM). 
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